uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
Show others and affiliations
2008 (English)In: Journal of Clinical Investigation, ISSN 0021-9738, E-ISSN 1558-8238, Vol. 118, no 1, 229-238 p.Article in journal (Refereed) Published
Abstract [en]

Patients with protein-losing enteropathy (PLE) fail to maintain intestinal epithelial barrier function and develop an excessive and potentially fatal efflux of plasma proteins. PLE occurs in ostensibly unrelated diseases, but emerging commonalities in clinical observations recently led us to identify key players in PLE pathogenesis. These include elevated IFN-gamma, TNF-alpha, venous hypertension, and the specific loss of heparan sulfate proteoglycans from the basolateral surface of intestinal epithelial cells during PLE episodes. Here we show that heparan sulfate and syndecan-1, the predominant intestinal epithelial heparan sulfate proteoglycan, are essential in maintaining intestinal epithelial barrier function. Heparan sulfate- or syndecan-1-deficient mice and mice with intestinal-specific loss of heparan sulfate had increased basal protein leakage and were far more susceptible to protein loss induced by combinations of IFN-gamma, TNF-alpha, and increased venous pressure. Similarly, knockdown of syndecan-1 in human epithelial cells resulted in increased basal and cytokine-induced protein leakage. Clinical application of heparin has been known to alleviate PLE in some patients but its unknown mechanism and severe side effects due to its anticoagulant activity limit its usefulness. We demonstrate here that non-anticoagulant 2,3-de-O-sulfated heparin could prevent intestinal protein leakage in syndecan-deficient mice, suggesting that this may be a safe and effective therapy for PLE patients.

Place, publisher, year, edition, pages
2008. Vol. 118, no 1, 229-238 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-98175DOI: 10.1172/JCI32335ISI: 000252122900024PubMedID: 18064305OAI: oai:DiVA.org:uu-98175DiVA: diva2:173538
Available from: 2009-02-16 Created: 2009-02-16 Last updated: 2011-06-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Li, Jin-Ping
By organisation
Department of Medical Biochemistry and Microbiology
In the same journal
Journal of Clinical Investigation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 291 hits
ReferencesLink to record
Permanent link

Direct link